Search results
MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
Pharmaceutical Technology· 2 days agoIn October 2023, MSD signed a licensing agreement with Daiichi Sankyo to develop and commercialise...
In October 2023, MSD signed a licensing agreement with Daiichi Sankyo to develop and commercialise...